AbbVie ABBV stock has declined 3.2% in a month. Shares of this large drugmaker dipped recently after it denied takeover talks ...

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

AbbVie slides after the company cut guidance, Wolfe Research downgraded the stock and the company pushed back on acquisition reports ...

ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to ...

AbbVie stock fell after denying Revolution Medicines buyout talks. Company also cut 2025 earnings forecast to $9.90-$9.94 per share.

AbbVie Inc. (NYSE:ABBV) is one of the best performing pharma stocks in 2025. AbbVie Inc. (NYSE:ABBV) was downgraded to Peer ...

AbbVie Inc. (NYSE:ABBV) is one of the 10 Goldman Sachs undervalued stocks to invest in. On January 14, 2026, Reuters reported ...

AbbVie’s ABBV stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since early July. The 50-day moving average is a short-term indicator, while the 200-day moving average ...

AbbVie’s solid stock performance is driven by rising investor optimism as the company has successfully navigated the loss of exclusivity (“LOE”) of its blockbuster drug, Humira, which once generated ...

The company's portfolio of properties, as of early November 2025, featured about 15,500 properties in all 50 U.S. states, the ...